Iovance Biotherapeutics, Inc. IOVA
11.00
0.20
1.85%
as of 25 Sep
- Market cap
- $4.9B
- P/E
- 0.0×
Follow IOVA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | — | 0.00 | 13.07 | 3.70 |
P/FCF ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | — | (22.68) | (29.27) | (18.56) |
P/B ratio |
— | — | — | — | — | — | — | 3.26 | 3.02 | 1.40 |
Price to Tangible BV |
— | — | — | — | — | — | — | 5.36 | 5.01 | 2.33 |
EV/Sales |
— | — | — | — | — | — | — | 0.00 | 11.11 | 2.58 |
EV/EBITDA |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | — | (4.49) | (5.16) | (2.25) |
EV/FCF |
— | — | — | — | — | — | — | (4.23) | (5.01) | (2.02) |
Quick Ratio |
33.51 | 15.15 | 32.54 | 7.86 | 11.47 | 5.65 | 5.16 | 2.54 | 3.21 | 2.74 |
Current Ratio |
34.12 | 15.56 | 33.02 | 8.10 | 11.59 | 5.69 | 5.24 | 2.79 | 3.74 | 3.20 |
Net Debt/EBITDA |
3.16 | 1.58 | 3.64 | 1.45 | 2.43 | 1.56 | 1.25 | 0.65 | 0.90 | 0.82 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.23% | 0.00% | 0.13% | 0.15% | 0.13% | 0.11% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.29 |
Operating CF/Net income |
0.32 | 0.85 | 0.82 | 0.80 | 0.79 | 0.67 | 0.74 | 0.81 | 0.95 | 0.77 |
Capex/Depreciation |
(1.68) | (1.06) | 3.19 | 3.07 | (15.57) | (1.88) | (0.95) | (0.75) | (0.29) | (0.84) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (75.55%) | (58.94%) | (40.41%) | (51.64%) | (54.34%) | (53.55%) | (70.61%) | (81.91%) | (57.48%) | (55.50%) | |
| (73.75%) | (56.26%) | (38.85%) | (47.86%) | (46.64%) | (44.28%) | (54.93%) | (61.49%) | (44.02%) | (42.88%) | |
ROIC |
(7,483.12%) | (53,748.26%) | 0.00% | 0.00% | (604.97%) | (181.13%) | (865.83%) | (94.15%) | (63.73%) | (62.77%) |
Return on Tangible Assets |
(61.32%) | (64.77%) | (26.65%) | (69.09%) | (40.53%) | (65.86%) | (80.33%) | (142.52%) | (83.87%) | (89.79%) |
Average Days of Receivables |
— | — | — | — | — | — | — | 46.35 | 154.26 | 114.21 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 28,023.04% | 168.36% | 113.95% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8,923.30% | 92.81% | 57.81% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.31 | 0.31 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5,267.03% | 66.82% | 23.37% |
Graham Net Nets |
— | — | — | — | — | — | — | 0.06 | 0.12 | 0.23 |
Graham Number |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | (23.21%) | (17.57%) | (41.03%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | (20.17%) | (16.97%) | (34.47%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.57 | 0.74 |
Operating CF per Share |
(0.59) | (1.21) | (1.04) | (1.28) | (1.48) | (1.49) | (1.84) | (1.54) | (1.22) | (0.85) |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.06) | (0.34) | (0.24) | (0.13) | (0.09) | (0.04) | (0.09) |
Free Cash Flow per Share |
(0.62) | (1.22) | (1.05) | (1.33) | (1.82) | (1.73) | (1.97) | (1.63) | (1.26) | (0.94) |
Cash per Share |
3.01 | 2.23 | 4.82 | 2.47 | 4.55 | 3.29 | 2.96 | 1.19 | 1.12 | 0.83 |
Shareholders Equity per Share |
3.02 | 2.23 | 4.79 | 2.40 | 4.75 | 4.05 | 3.14 | 2.49 | 2.45 | 1.95 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.02 | 2.23 | 4.79 | 2.40 | 4.75 | 4.05 | 3.14 | 2.49 | 2.45 | 1.95 |
Free Cash Flow |
(34.19) | (79.74) | (102.45) | (165.81) | (251.92) | (265.51) | (313.18) | (384.11) | (364.05) | (336.24) |
Working Capital |
164.54 | 139.70 | 460.98 | 277.41 | 581.23 | 418.76 | 387.63 | 197.54 | 334.68 | 304.33 |
Capital Expenditures |
(1.52) | (1.03) | (1.20) | (6.92) | (46.79) | (37.57) | (20.42) | (22.29) | (11.07) | (33.84) |
Net Current Asset Value |
164.54 | 139.40 | 460.75 | 270.81 | 524.14 | 352.28 | 314.77 | 112.11 | 257.00 | 228.10 |
EV/EBIT |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.75 | 0.07 | 0.13 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (37,345.42%) | (226.84%) | (148.38%) |
Price to Operating Income |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.38 | 0.40 | (0.14) | (0.26) | 0.05 | 0.20 | 0.21 | 0.26 | 0.35 | 0.31 |
Cash ROIC |
(10.51%) | (27.90%) | (11.12%) | (27.43%) | (20.55%) | (29.18%) | (40.93%) | (54.98%) | (44.64%) | (43.55%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | 0.00 | 4.72 | 3.47 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 3.08 | 6.97 |
Inventory Turnover |
— | — | — | — | — | — | — | 0.00 | 3.01 | 3.36 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11,703.67 | 107.68 | 46.70 |
Days of Inventory on Hand |
— | — | — | — | — | — | — | 3,664.84 | 201.66 | 108.92 |
Average Receivables |
— | — | — | — | — | — | — | — | 34.75 | 75.89 |
Average Payables |
0.91 | 1.05 | 1.99 | 9.15 | 14.54 | 20.45 | 26.99 | 29.86 | 30.32 | 24.83 |
Average Inventory |
— | — | — | — | — | — | — | — | 30.95 | 51.60 |
Average Assets |
138.77 | 163.63 | 318.10 | 412.74 | 556.56 | 772.90 | 720.66 | 722.17 | 845.39 | 911.80 |
Average Common Equity |
135.47 | 156.19 | 305.83 | 382.58 | 477.73 | 639.07 | 560.65 | 542.12 | 647.51 | 704.49 |
Columns are period end dates